Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H ( (HK:9989) ).
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. has scheduled a board meeting for April 29, 2026 to review and approve its first-quarter results for the period ended March 31, 2026. The announcement signals that the company is preparing to release its quarterly financial performance to the market, a step that may offer investors and stakeholders fresh insight into its recent operational and financial trends.
The most recent analyst rating on (HK:9989) stock is a Sell with a HK$4.31 price target. To see the full list of analyst forecasts on Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H stock, see the HK:9989 Stock Forecast page.
More about Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. is a China-based pharmaceutical group listed in Hong Kong, operating through a network of subsidiaries. The company focuses on the development, manufacturing and sale of pharmaceutical products, positioning itself within the broader healthcare and life sciences sector.
Average Trading Volume: 765,947
Technical Sentiment Signal: Hold
Current Market Cap: HK$17.5B
For detailed information about 9989 stock, go to TipRanks’ Stock Analysis page.